Who are Folfiri's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Eloxatin, Consolidation Chemotherapy, Cytokine-induced killer cells+ FOLFOX4, CVP, HAIC of FOLFOX, Methotrexate + targeted therapy administration.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/folfiri.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Folfiri — Competitive Intelligence Brief

Folfiri (folfiri) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: chemotherapy. Area: Oncology.

marketed chemotherapy DNA replication and repair Oncology Live · refreshed every 30 min

Target snapshot

Folfiri (folfiri) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Folfiri TARGET	folfiri	Pfizer	marketed	chemotherapy	DNA replication and repair
Eloxatin	Oxaliplatin	Yakult Honsha	marketed	Platinum-based chemotherapy agent	DNA	2002-01-01
Consolidation Chemotherapy	Consolidation Chemotherapy	National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos	marketed	Combination chemotherapy regimen
Cytokine-induced killer cells+ FOLFOX4	Cytokine-induced killer cells+ FOLFOX4	China Meitan General Hospital	marketed	Cell therapy combined with chemotherapy
CVP	CVP	SCRI Development Innovations, LLC	marketed	Combination chemotherapy regimen
HAIC of FOLFOX	HAIC of FOLFOX	Tianjin Medical University Cancer Institute and Hospital	marketed	Chemotherapy combination (regional delivery)
Methotrexate + targeted therapy administration	Methotrexate + targeted therapy administration	University Hospital, Strasbourg, France	marketed	Combination chemotherapy with targeted agent	Dihydrofolate reductase (methotrexate component); targeted agent varies by protocol

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (chemotherapy class)

Pfizer · 3 drugs in this class
Chengdu New Radiomedicine Technology Co. LTD. · 1 drug in this class
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · 1 drug in this class
Chinese Society of Lung Cancer · 1 drug in this class
Hutchmed · 1 drug in this class
Prof. Massimo Aglietta · 1 drug in this class
Sanofi · 1 drug in this class
Sun Yat-sen University · 1 drug in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Swiss Cancer Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Folfiri — Competitive Intelligence Brief. https://druglandscape.com/ci/folfiri. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab